# SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

> **NCT00418938** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 266 (actual)

## Conditions studied

- Cancer
- Colon Cancer
- Colorectal Cancer
- Metastatic Cancer
- Rectal Cancer
- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Bevacizumab
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan
- **DRUG:** 5-Fluorouracil

## Key facts

- **NCT ID:** NCT00418938
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-01
- **Primary completion:** 2012-05-10
- **Final completion:** 2013-04-01
- **Target enrollment:** 266 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418938, "SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00418938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*